

Mayne Pharma appoints a new vice president

18 June 2014 | News | By BioSpectrum Bureau



Singapore: Australian drug maker Mayne Pharma announced Mr Blake Cullen as the new vice president of business development, for its US generic products division.

The company spokesperson said that Mr Cullen would play an instrumental role in enriching the fastest growing generic business in the US with his expertise and pursue new business opportunities on behalf of Mayne Pharma's generics products division.

Mayne Pharma has successfully established a steep growth curve within 10 years in the US, marketing more than 20 products. The firm also has 25 products under development with 13 ANDAs filed with the FDA.

Mr Stefan Cross, president of Mayne Pharma said that Mr Cullen's affiliation would help the firm use his expertise in building a robust product pipeline of corporate value.

He added that Mr Cullen's market experience and his established relationships in the industry would help in expanding the company's US businesses.

Mr Cullen brings into Mayne Pharma over 15 years of experience in the industry in areas of strategic planning, mergers and acquisitions, and product in-licensing and out-licensing. He has worked with giant drug companies, including Rhodes Pharma and Libertas Pharma.